📰 John Savin News
Page 2 - John Savin News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from John Savin. Real-time updates on events, politics, business and more.
January 24, 2023
Proactive research analyst John Savin speaks to Thomas Warner after publishing a new report on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP,...
January 18, 2023
Proactive research analyst John Savin speaks to Thomas Warner about his latest research note on Creo Medical Group PLC (AIM:CREO). He gives his take on how...
December 15, 2022
Proactive research analyst John Savin speaks to Thomas Warner after publishing a new report on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP,...
December 15, 2022
EQS-News: Oxford Cannabinoid Technologies Holdings PLC Proactive research analyst John Savin on Oxford Cannabinoid Technologies 15.12.2022 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive UK Ltd+44 20 7989 0813uk@proactiveinvestors....
July 5, 2022
Proactive Research analyst John Savin explains the investment case for Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), which directly sells a fully approved...
June 29, 2022
Numinus Wellness Inc has created a North American integrated business delivering mental health wellness services through clinics offering evidence-based...
May 16, 2022
John Savin, a research analyst at Proactive, joined Katie to talk about Numinus Wellness. Numinus runs five psychedelic wellness clinics in Canada and is on...
March 23, 2022
Proactive Research analyst John Savin presents his research Tiziana Life Sciences which uses its delivery technology to administer its fully human...
February 17, 2022
Proactive Research analyst John Savin presents his analysis on Open Orphan PLC (AIM:ORPH, OTC:OPORF)s (Open Orphan PLC (AIM:ORPH,...
January 15, 2021
Edison Investment Research Limited: ReNeuron Group (RENE): Continuing to Gain Clinical Data in Eye Disease LONDON, UK / ACCESSWIRE / January 15, 2021 / After an eventful 2020, ReNeuron released updated 12-month Phase ll data in January on its lead human retinal progenitor cell (hRPC) project. This continues to show a consistent and robust, sustained average gain in visual acuity in retinitis pigmentosa (RP). A continuation study in nine patients using two million cells is underway with three- a...